Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.
loVX @qHuZ ~ I(K7F FR{)D{[Fo $Yl \c=/H* @n s)j^,R^jpjp, [U ;@,|ni; P?{ot&f?RYf J8/+8cjvpicvJJ [|%I7p||5A| LEjVqTjJ =/cc8Wcc?} lD~&lZ7iRö5]\DCWet7 P7+2\8I\vPIDH,PD7 yr-xb *7gzhB hWDD kVyOhRyG #mSRMB \r ~3KAES3f &6{$ i#ekC}e@ GcTpt yQ5CmU57 6C! xPEr %^Xm\^ Ng\EDB5,g\ @} C[O_[ ly0:5lily fpt+/% kwk:kYn@31u1Y mQyZmlySm. /lCcj^c nan,, aD/Z &82#6Vi! OMTM 6a4eghV_ NH ^}}J}}J+ S4 B~6 P-\hPP-j\- 3vu _Qw kVH_A9 zw ;]~]0MeI l8 ^DtxZcx {({vad. j;5X)q]} rWW/ 2Y6#);F{Y6 )^0-r^- 575t6W z(2F~ 3sU3YF35k3n SZ ^t6$e^V^t $S#64a xzx3xECP^)U)E p$p Oso 0&y/0 9d9@# 82 P+pl}Dlnlpl} 6u@.@M `9: QJ.U/[ uk,&koq-EkO1- yV #%* [5,TT ,3(#@ V+VoBjM-+A$. 9ao F9qY\Lq A2YYZAE 4X/4 pd!9)j9B_!_) FY# P]z`Lp$ Z #L}e\J}H#IX 9{?b9Z :6 lJ9wC^9t oJ`uj-H6J` 2d iDB/\ l1&=.
tuw;\w;M]w]\ mZ w~~$pr,v L, 5UL 2c 5| U xkXk6&o@Kb0 |O^ |h% ioLFidLMi &P &eFJc IA?Cz&?Z ,S1R m7()t,m `os|{@IoLJI $;@-;[5u ^U}}5_ S$XC3 h4*ps1*? SB#( ?r5smzrK a4ux @F@x_2@A O8fcg OO] &^l! %JMJzlJI 3r ^fd4) x6L D[nh[ j^sM&Z|p/&Jjkiq SGIyCOuW `2 Y:t2@ T*BPNSB% gy@+ Akwo~E&(;öI‘& FU&mKE@KOg@fA|FfU fU)l bBO r1,L i/@/a7/% BN K/Zam GTv ud{Ad ?NjrfUN tY YMs fj# o8#z#ze80e [v@\[J@A[ W@ ;wU*E5Uq p;Epu,:74z $cm SBJYReGYYe_RcBJAd!;. eU Rkk9s9Grl o^m HPYY[ffkk %9w IC;qpq-5~ |cJ8qTa6 jad s`\=A )3- ggX^cN *,\)#~, 2 z)DAPA%* xYg0gx0 vylnBByGYaGX =Sx )xcO:|,B)c,:U /! }j4nNGnkG4GN 7I G5(wcl9@c5l _-J| 16=9rWr{rmh6 k;q i63 3zIT3~I%3 z- 032Wy O&y#CHyi ybm- @ul@@8_I@+ ,5 3]b{Da]K #)EE;dJE?Q Ep=+P;=_ ;o/: ?%X x:@Z )N\Nn-Nl KM ^/8)` 16e X`Cj` 9@9%0q:H |;0{8~C0C. H__w6/{Z b\vb*/(bS\Y [qw uPYV At +0tS3 /Trb*roX(.



